Special Issue

Protein Aggregation: Molecular Mechanisms, Determinants and Therapeutic Approaches

Message from the Guest Editor

Macromolecular protein assemblies including protein aggregates, biomolecular condensates, and ordered amyloid fibril formation have been associated with various widespread diseases, spanning from major neurodegenerative disorders to certain forms of cancer. At the same time, amyloid formation has also been shown to support important biological functions starting from humans and extending to single-cell organisms. The recent efflux of structural information on amyloid architecture, combined with studies on the molecular determinants and mechanisms that promote self- and heterotypic assembly, has highlighted certain unresolved properties of protein aggregates, such as structural polymorphism and its differential association to disease, selective vulnerability of specific cell types to certain toxic aggregate species, and complex spreading patterns, while also promoting the design of novel therapeutic approaches against this group of diseases.

Guest Editor

Dr. Nikolaos N. Louros VIB - KU Leuven, 3000 Leuven, Belgium

Deadline for manuscript submissions

closed (30 November 2022)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/108799

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).